rs3754048 — APH1A -980C/G

APH1A Promoter Variant — Elevated Gamma-Secretase Activity and Alzheimer's Risk

A regulatory variant 2 kb upstream of APH1A sits at the molecular origin of amyloid precursor protein (APP) cleavage. APH1A¹¹ APH1A
anterior pharynx-defective 1A, a seven-transmembrane scaffolding subunit of the gamma-secretase complex is an obligate structural component of the enzyme that cuts APP into fragments, including the neurotoxic Aβ42 peptide — the primary driver of amyloid plaque formation in Alzheimer's disease. rs3754048 is a single-nucleotide change in the APH1A promoter region where one allele creates a stronger binding site for the YY1²² YY1
Yin Yang 1, a transcription factor that can activate or repress gene expression depending on context and co-factors transcription factor, switching on higher APH1A production and consequently greater gamma-secretase activity.

The Mechanism

APH1A is on the minus strand of chromosome 1. The variant described as -980C/G in the literature (coding-strand notation) corresponds to G>C on the GRCh38 plus strand. The C allele (plus strand) — the paper's coding-strand G — creates an enhanced YY1 binding site in the APH1A promoter. Qin et al. 2011³³ Qin et al. 2011
Qin W et al. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer's disease. Aging Cell. 2011 demonstrated this through electrophoretic mobility shift assay (EMSA): the C allele binds YY1 more avidly, and YY1 overexpression activates the APH1A promoter 2.7-fold in both N2A neuroblastoma and HEK293 cells. The consequence is measurably higher APH1A protein levels and elevated gamma-secretase activity in individuals carrying the C allele, which shifts APP cleavage toward more Aβ42 production.

The connection to sleep runs through Aβ's role as a circadian regulator. Soluble Aβ oscillates with the sleep-wake cycle — levels are highest during waking and fall during sleep as the glymphatic system⁴⁴ glymphatic system
the brain's cerebrospinal-fluid-driven waste-clearance network, most active during slow-wave sleep flushes it. Elevated gamma-secretase activity from the C allele increases the baseline Aβ load that the glymphatic system must clear each night. Over decades, even a modest increase in production can tip the balance toward accumulation, particularly during periods of sleep disruption.

The Evidence

The association between rs3754048 and Alzheimer's disease was first reported by Wang & Jia 2009⁵⁵ Wang & Jia 2009
Wang Y, Jia J. Association between promoter polymorphisms in anterior pharynx-defective-1a and sporadic Alzheimer's disease in the North Chinese Han population. Neurosci Lett. 2009 in 256 sporadic Alzheimer's disease patients and 276 controls from North China. The coding-strand G genotype and G allele were significantly more frequent in AD cases (genotype P=0.038, allele P=0.01 in the full cohort; genotype P=0.048, allele P=0.016 in APOE ε4-positive subjects). The interaction with APOE ε4 suggests an additive or synergistic risk pathway.

The functional basis for this association was established by Qin et al. 2011⁶⁶ Qin et al. 2011
Qin W et al. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer's disease. Aging Cell. 2011, which validated the association in two additional Chinese cohorts (450 AD and 450 controls in the replication arm) and provided the mechanistic data: YY1-driven 2.7-fold promoter activation, increased APH1A protein expression, and elevated gamma-secretase activity measured in carrier tissue samples. Evidence is graded moderate: the studies are replicated and the functional mechanism is clear, but both cohorts are Chinese, sample sizes are modest by modern GWAS standards, and no large-scale multi-ancestry replication exists.

The sleep dimension is supported by complementary evidence. Lim et al. 2014⁷⁷ Lim et al. 2014
Lim MM et al. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014 established the reciprocal loop: as Aβ accumulates, sleep-wake fragmentation worsens; as sleep quality degrades, glymphatic clearance falls and Aβ accumulates faster. Wu et al. 2019⁸⁸ Wu et al. 2019
Wu H et al. The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. Front Neuroendocrinol. 2019 extended this to circadian disruption, showing that clock misalignment impairs the glymphatic-vascular-lymphatic clearance of Aβ and tau, reduces melatonin, and increases neuronal oxidative stress. For APH1A C-allele carriers, this means the upstream production tap is open wider — making sleep quality and circadian alignment more consequential than for the general population.

Practical Actions

The APH1A C allele does not cause Alzheimer's disease; it shifts the balance of the gamma-secretase complex toward higher Aβ42 output. Practical interventions for C-allele carriers focus on two complementary strategies: protecting glymphatic clearance of Aβ during sleep, and monitoring amyloid-sensitive biomarkers to detect accumulation early. The evidence for melatonin as a specific intervention in APH1A-variant carriers comes from the circadian-amyloid literature rather than direct trials in this genotype, so it is graded accordingly.

Interactions

rs3754048 interacts with APOE ε4 status (rs429358). Wang & Jia 2009 found the association strengthened in APOE ε4-positive subjects — the two risk factors appear to act in the same downstream pathway (Aβ production and clearance) and may have super-additive effects. rs34714364 is the related APH1A/CA14 locus chronotype variant already in the GeneOps database; it tags regulatory variation at the APH1A locus affecting circadian preference, while rs3754048 is the directly functional promoter variant affecting gamma-secretase activity. These two APH1A-locus variants complement each other for a complete picture of APH1A-mediated Alzheimer's and sleep pathology risk.